South San Francisco, CA, United States
South San Francisco, CA, United States

Sunesis Pharmaceuticals is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of small molecular therapeutics for oncology and other unmet medical needs. The company was founded by Jim Wells,.Founded in 1998, Sunesis filed and completed an IPO in 2005. It is listed on NASDAQ as SNSS. Wikipedia.


Time filter

Source Type

Methods of preparing (+)-1,4-dihydro-7-[(3S,4S)-3-methoxy-4-(methylamino)-1-pyrrolidinyl]-4-oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acid are disclosed. Also provided are pharmaceutical compositions comprising (+)-1,4-dihydro-7-[(3S,4S)-3-methoxy-4-(methylamino)-1-pyrrolidinyl]-4-oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acid, and methods of treatment using such compositions.


Patent
Biogen MA Inc. and Sunesis Pharmaceuticals | Date: 2016-02-29

The present invention provides compounds useful as inhibitors of Tec family kinases, compositions thereof, and methods of using the same.


Methods of treating cancers are disclosed. The methods encompass the administration of SNS-595 in combination with cisplatin and carboplatin.


Patent
Sunesis Pharmaceuticals | Date: 2016-05-16

Compounds and compositions for treating, preventing or managing cancer are disclosed. The compositions provided herein comprise SNS-595 and N-desmethyl-SNS-595. Also provided are pharmaceutical compositions comprising the compounds and methods of treatment using the compounds and compositions.


Methods of treating, preventing or managing hematologic disorders, such as leukemia are disclosed. The methods encompass the administration of SNS-595. Also provided are methods of treatment using this compound with chemotherapy, radiation therapy, hormonal therapy, biological therapy or immunotherapy. In certain embodiments, the method of treatment comprise administering SNS-595 in combination with Ara-C. Pharmaceutical compositions and single unit dosage forms suitable for use in the methods are also disclosed.


Patent
Biogen MA Inc. and Sunesis Pharmaceuticals | Date: 2016-05-27

The present invention provides a compound, solid forms, and compositions thereof, which are useful as inhibitors of Brutons tyrosine kinase and which exhibit desirable characteristics for the same. The present invention also provides methods of making provided compound and solid forms.


Patent
Sunesis Pharmaceuticals and Dainippon Sumitomo | Date: 2016-08-10

The invention provides a compound for use in a method for treating a solid tumor in a patient, wherein the compound is (+)-1,4- dihydro-7-[(3S,4S)-3-methoxy-4-(methylamino)-1-pyrrolidinyl]-4-oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acid and the method comprises administering the compound to the patient in a dose of 10 mg/m^(2) to 100 mg/m^(2).


Patent
Biogen MA Inc. and Sunesis Pharmaceuticals | Date: 2016-06-29

The present invention provides compounds and compositions thereof which are useful as inhibitors of Brutons tyrosine kinase and which exhibit desirable characteristics for the same.


Patent
Biogen MA Inc. and Sunesis Pharmaceuticals | Date: 2016-01-25

The present invention provides compounds useful as inhibitors of Btk, compositions thereof, and methods of using the same.


Patent
Millennium Pharmaceuticals Inc. and Sunesis Pharmaceuticals | Date: 2016-09-21

The present invention provides compounds useful as inhibitors of PDK1. The present invention also provides compositions thereof, and methods of treating PDK1-mediated diseases.

Loading Sunesis Pharmaceuticals collaborators
Loading Sunesis Pharmaceuticals collaborators